- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05325099
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
Study of the Effect of Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
Acute kidney injury (AKI) is increasing worldwide in recent years and is a major risk factor of chronic kidney disease (CKD). AKI, acute kidney disease (AKD) and CKD form a continuum whereby initial kidney injury leads to ongoing renal injury and eventually end-stage renal disease if no effective treatment is applied. Nevertheless, there are no useful pharmacotherapies approved clinically for the treatment of AKI and subsequent CKD.
Previous studies of the investigators have confirmed that pericytes are the primary cell source of scar-producing myofibroblasts. Furthermore, the investigators had demonstrated that significant epigenetic modification in transcriptome analysis of pericytes develops in different stage of AKI-CKD continuum. These epigenetic memory made pericytes obtain proliferative and pro-fibrotic phenotypes in activated status and persist in inactivated status. Demethylation by azacitidine prevented AKI-CKD transition, and attenuated fibrogenesis induced by a second adenine-AKI.
Azacitidine has been approved in the United States Food and Drug Administration and European Union for treatment of adult acute myeloid leukemia (AML), particularly recommended front-line treatment for older patients with acute myeloid leukemia who are not candidates for intensive treatment regimens. Dosage of azacitidine in clinical trial is calculated according to previous study and is lower than chemotherapeutic dose. Low dose azacitidine has demethylation effect and less cytotoxicity.
CSA-AKI is the second commonest cause of AKI in ICU. The investigators plan to initiate a double-blind randomized controlled trial (RCT) to recruit CSA-AKI patients. The patients will be divided as azacitidine group and placebo group. Patients in azacitidine group will receive three doses of low dose azacitidine in one week when AKI is diagnosed. After that, the investigators will follow up their renal function and urine protein every three month. Primary composite outcomes include a decline of at least 50% in the estimated GFR, an increase of urine protein-creatinine ratio (UPCR) over 1000 mg/g, and the development of end stage renal disease (ESRD). Secondary outcome is overall mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute kidney injury (AKI) is increasing worldwide in recent years and is a major risk factor of chronic kidney disease (CKD). An episode of AKI is not only associated with significant risk of short- and long-term morbidity and mortality but also a tremendous burden to patients, societies, and health care system. AKI, acute kidney disease (AKD) and CKD form a continuum whereby initial kidney injury leads to ongoing renal injury and eventually end-stage renal disease if no effective treatment is applied. Nevertheless, there are no useful pharmacotherapies approved clinically for the treatment of AKI and subsequent CKD. Current management can only focus on avoiding risk factors to prevent AKI and supportive care after diagnosis of AKI.
Pericytes, sharing developmental origins with fibroblasts, are the collagen-producing cells contacted with the microvascular. Previous studies of the investigators have confirmed that pericytes are the primary cell source of scar-producing myofibroblasts. Furthermore, the investigators had demonstrated that significant epigenetic modification in transcriptome analysis of pericytes develops in different stage of AKI-CKD continuum. These epigenetic memory made pericytes obtain proliferative and pro-fibrotic phenotypes in activated status and persist in inactivated status. The investigators found methylation of Ybx2 gene and other four repressor genes of αSMA were induced by TGF-b1 after AKI. Demethylation by azacitidine recovered the microvascular stabilizing function of aPericytes, reversed the profibrotic property of iPericytes, prevented AKI-CKD transition, and attenuated fibrogenesis induced by a second adenine-AKI. As a result, azacitidine is a potential therapeutic agents to prevent AKI-CKD continuum by its demethylating effect.
Azacitidine has been approved in the United States Food and Drug Administration and European Union for treatment of adult acute myeloid leukemia (AML), particularly recommended front-line treatment for older patients with acute myeloid leukemia who are not candidates for intensive treatment regimens. Azacitidine is used in clinical trial of other malignancies such as breast cancer or lung cancer. Dosage of azacitidine is calculated according to previous study and is lower than chemotherapeutic dose. Low dose azacitidine has demethylation effect and less cytotoxicity.
CSA-AKI is the second commonest cause of AKI in ICU. 8.2% patients after cardiac surgery in our hospital had severe AKI defined as Kidney Disease Improving Global Outcomes (KDIGO) criteria stage 2 or 3. Therefore, the investigators plan to initiate a double-blind randomized controlled trial (RCT) to recruit CSA-AKI patients. The patients will be divided as azacitidine group and placebo group. Patients in azacitidine group will receive three doses of low dose azacitidine in one week when AKI is diagnosed. After that, the investigators will follow up their renal function and urine protein every three month. Primary composite outcomes include a decline of at least 50% in the estimated GFR, an increase of urine protein-creatinine ratio (UPCR) over 1000 mg/g, and the development of end stage renal disease (ESRD). Secondary outcome is overall mortality. If the results demonstrated the benefit of azacitidine on the prevention of AKI-CKD continuum, the investigators can optimize the strategies and guideline of post-AKI care and the incidence of CKD and ESRD will decrease.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Taipei City, Taiwan, 116
- Yu Hsiang Chou
-
Contact:
- Yu-Hsiang Chou, PhD
- Phone Number: 0972651261
- Email: chouyuhsiang@yahoo.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with cardiac surgery associated-AKI, stage 2 and stage 3
Exclusion Criteria:
- Chronic kidney disease
- Decompensated heart failure (EF < 45%)
- Liver cirrhosis, child B or C
- Acute infection
- Acute bleeding
- Long-term use of immunosuppressant other than azacitidine
- Patients with active cancer other than acute leukemia or myelodysplastic syndrome
- Leukopenia, anemia or thrombocytopenia
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AKI patient with azacitidine treatment
azacitidine (subcutaneous injection)
|
azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
Other Names:
|
Placebo Comparator: AKI patient with placebo treatment
Placebo drug (subcutaneous injection)
|
Placebo (subcutaneous injection) QOD x 3 times
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal composite outcome
Time Frame: 2 years after recruitment
|
|
2 years after recruitment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall mortality and cardiovascular death
Time Frame: 2 years after recruitment
|
2 years after recruitment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202110100MINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Disease
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Taipei Medical University Shuang Ho HospitalTaipei Medical University; National Health Research Institutes, TaiwanUnknownRenal Insufficiency, Chronic | Acute Kidney Injury | Decision Support Systems, Clinical | Acute Kidney Disease
-
Hospital de Clinicas de Porto AlegreRecruitingCritical Illness | Acute Kidney Injury | Fluid Overload | Renal Insufficiency, Acute | Volume Overload | Kidney; Disease, AcuteBrazil
-
Renibus Therapeutics, Inc.CompletedKidney Failure, AcuteUnited States
-
Region StockholmNot yet recruitingChronic Kidney Disease | Acute Kidney Injury | Cardiac Surgery | Acute Kidney Disease | Renal Resistive Index
-
Nanjing First Hospital, Nanjing Medical UniversityCompleted
-
Matthew Harer, MDUnknownNeonatal Acute Kidney Injury | Childhood Chronic Kidney DiseaseUnited States
-
Thammasat UniversityUnknown
-
Karolinska InstitutetCompletedChronic Kidney Disease | Acute Kidney Injury | Acute Kidney DiseaseSweden
-
University Hospital, BordeauxMinistry of Health, FranceCompletedRenal Transplantation | End-stage Chronic Renal Disease | Severe Acute Kidney FailureFrance
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
CelgeneCompletedMyelodysplastic SyndromesUnited States